As CD4+ T-LGLL is a rare disease, previous studies evaluating the clinical impact of STAT5B mutations have been limited in size, and no deep TCR profiling has been performed with modern sequencing and bioinformatic tools [23–25]. The gene discussed is CD4; the disease is T-cell large granular lymphocyte leukemia.